JP2017501694A - 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析 - Google Patents

診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析 Download PDF

Info

Publication number
JP2017501694A
JP2017501694A JP2016536918A JP2016536918A JP2017501694A JP 2017501694 A JP2017501694 A JP 2017501694A JP 2016536918 A JP2016536918 A JP 2016536918A JP 2016536918 A JP2016536918 A JP 2016536918A JP 2017501694 A JP2017501694 A JP 2017501694A
Authority
JP
Japan
Prior art keywords
cancer
exosomes
exosome
patient
gpc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016536918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501694A5 (enExample
Inventor
ラフ カルーリ，
ラフ カルーリ，
ソニア メロ，
ソニア メロ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2017501694A publication Critical patent/JP2017501694A/ja
Publication of JP2017501694A5 publication Critical patent/JP2017501694A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
JP2016536918A 2013-12-04 2014-12-04 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析 Ceased JP2017501694A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911863P 2013-12-04 2013-12-04
US61/911,863 2013-12-04
PCT/US2014/068630 WO2015085096A1 (en) 2013-12-04 2014-12-04 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019148579A Division JP2019198327A (ja) 2013-12-04 2019-08-13 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析

Publications (2)

Publication Number Publication Date
JP2017501694A true JP2017501694A (ja) 2017-01-19
JP2017501694A5 JP2017501694A5 (enExample) 2017-12-21

Family

ID=53274132

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016536918A Ceased JP2017501694A (ja) 2013-12-04 2014-12-04 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
JP2019148579A Withdrawn JP2019198327A (ja) 2013-12-04 2019-08-13 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
JP2021110830A Active JP7138372B2 (ja) 2013-12-04 2021-07-02 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019148579A Withdrawn JP2019198327A (ja) 2013-12-04 2019-08-13 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
JP2021110830A Active JP7138372B2 (ja) 2013-12-04 2021-07-02 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析

Country Status (13)

Country Link
US (3) US9921223B2 (enExample)
EP (1) EP3076949B1 (enExample)
JP (3) JP2017501694A (enExample)
AU (3) AU2014360344B2 (enExample)
CA (1) CA2936100A1 (enExample)
DK (1) DK3076949T3 (enExample)
HR (1) HRP20192131T1 (enExample)
HU (1) HUE046489T2 (enExample)
LT (1) LT3076949T (enExample)
NZ (1) NZ721720A (enExample)
SI (1) SI3076949T1 (enExample)
WO (1) WO2015085096A1 (enExample)
ZA (1) ZA201604468B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10959952B2 (en) 2015-06-10 2021-03-30 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
JP2021519296A (ja) * 2018-03-28 2021-08-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 治療用物質を標的送達するためのエキソソームの使用法
JP2022519326A (ja) * 2019-02-08 2022-03-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出
WO2023210644A1 (ja) * 2022-04-26 2023-11-02 国立大学法人東京大学 がん細胞由来細胞外小胞群の単離濃縮方法、分析方法、薬剤選択方法、キット、及び抗がん剤

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2006116362A2 (en) 2005-04-25 2006-11-02 The Trustees Of Boston University Structured substrates for optical surface profiling
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
EP2971162B1 (en) 2013-03-15 2019-05-08 Board Of Regents, The University Of Texas System Mirna biogenesis in exosomes for diagnosis and therapy
DK3076949T3 (da) * 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer
WO2015095794A1 (en) 2013-12-20 2015-06-25 Advanced ReGen Medical Technologies, LLC Compositions for cellular restoration and methods of making and using same
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
EP3125907A4 (en) * 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
US11339441B2 (en) * 2015-05-12 2022-05-24 The Research Foundation For The State University Of New York Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
US10345310B2 (en) 2015-06-09 2019-07-09 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
CA2999283A1 (en) 2015-09-22 2017-03-30 Trustees Of Boston University Multiplexed phenotyping of nanovesicles
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP7033082B2 (ja) * 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド 表面マーカーを有するエキソソームの検出
SG11201807401RA (en) * 2016-03-15 2018-09-27 Codiak Biosciences Inc Therapeutic membrane vesicles
WO2017190000A1 (en) 2016-04-29 2017-11-02 Advanced ReGen Medical Technologies, LLC Microrna compositions and methods of making and using same
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3472623A4 (en) * 2016-06-21 2020-01-15 Nant Holdings IP, LLC TREATMENT OF CANCER GUIDED BY EXOSOME
CN106124282B (zh) * 2016-07-26 2019-07-16 广州海力特生物科技有限公司 一种叠层离心过滤分离提取外泌体的方法
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
IL269483B2 (en) * 2017-03-21 2024-04-01 Exoprother Medical Ltd Native cell derived vesicles containing tumor suppressor proteins for therapy
GB2560897A (en) * 2017-03-23 2018-10-03 Lotvall Jan Tissue-derived extracellular vesicles and their use as diagnostics
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107338306A (zh) * 2017-07-23 2017-11-10 嘉兴允英医学检验有限公司 一种用于GPC1mRNA表达检测的试剂盒
JP2020529477A (ja) * 2017-08-04 2020-10-08 シーダーズ—シナイ メディカル センター がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
CN111566484A (zh) * 2017-11-09 2020-08-21 宾夕法尼亚大学董事会 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
US20210285952A1 (en) 2017-12-01 2021-09-16 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
AU2018394238A1 (en) * 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
EP3740576A4 (en) 2018-01-18 2021-10-20 Advanced Regen Medical Technologies, LLC THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
JP7474702B2 (ja) * 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
WO2019199803A1 (en) * 2018-04-09 2019-10-17 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CN112105736A (zh) * 2018-05-04 2020-12-18 西格马-奥尔德里奇有限责任公司 生产具有降低宿主细胞蛋白水平的重组蛋白
WO2019232321A1 (en) 2018-06-01 2019-12-05 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
US11119798B2 (en) 2018-11-15 2021-09-14 Sternum Ltd. Applying control flow integrity verification in intermediate code files
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
WO2020146390A1 (en) 2019-01-09 2020-07-16 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
WO2020160402A1 (en) * 2019-02-01 2020-08-06 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
WO2020219699A1 (en) * 2019-04-23 2020-10-29 Children's Medical Center Corporation Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb)
JP7462452B2 (ja) * 2020-03-27 2024-04-05 株式会社日立製作所 培養細胞の分化レベルを評価するための評価装置および評価方法、並びに自動細胞培養システム
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
US20230340606A1 (en) * 2021-09-09 2023-10-26 The Regents Of The University Of California Extracellular repetitive rna biomarkers of mutant kras cancers
US20250011876A1 (en) * 2021-11-02 2025-01-09 The Regents Of The University Of California Extracellular rna signatures of mutant kras(g12c) cancers
US20250290919A1 (en) * 2022-05-06 2025-09-18 The Trustees Of The University Of Pennsylvania Ultrasensitive single extracellular vesicle detection using high throughput droplet digital enzyme-linked immunosorbent assay
WO2024047441A1 (en) * 2022-09-01 2024-03-07 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method for monitoring tumor burden in subjects during therapeutic intervention
WO2024073671A1 (en) * 2022-09-30 2024-04-04 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510663A (ja) * 2008-02-01 2011-04-07 ザ ジェネラル ホスピタル コーポレイション 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US20120196285A1 (en) * 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
US9309559B2 (en) * 2013-04-15 2016-04-12 Albert Einstein College Of Medicine, Inc. Simultaneous extraction of DNA and RNA from FFPE tissues
DK3076949T3 (da) * 2013-12-04 2019-11-25 Univ Texas Fremgangsmåde til isolering af kræftcelle-afledte eksosomer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510663A (ja) * 2008-02-01 2011-04-07 ザ ジェネラル ホスピタル コーポレイション 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MOL. CELL BIOL., vol. 5, JPN6018040506, 11 April 2013 (2013-04-11), pages 227 - 238, ISSN: 0003899126 *
THE PROSTATE, vol. 72, JPN6018040507, 2012, pages 1736 - 1745, ISSN: 0003899127 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10959952B2 (en) 2015-06-10 2021-03-30 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
JP2021519296A (ja) * 2018-03-28 2021-08-10 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 治療用物質を標的送達するためのエキソソームの使用法
JP2022519326A (ja) * 2019-02-08 2022-03-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出
WO2023210644A1 (ja) * 2022-04-26 2023-11-02 国立大学法人東京大学 がん細胞由来細胞外小胞群の単離濃縮方法、分析方法、薬剤選択方法、キット、及び抗がん剤

Also Published As

Publication number Publication date
US20180045728A1 (en) 2018-02-15
AU2019200573A1 (en) 2019-02-21
US10598665B2 (en) 2020-03-24
WO2015085096A1 (en) 2015-06-11
EP3076949A1 (en) 2016-10-12
SI3076949T1 (sl) 2020-01-31
EP3076949A4 (en) 2017-11-22
HRP20192131T1 (hr) 2020-02-21
NZ721720A (en) 2022-04-29
ZA201604468B (en) 2024-01-31
US20200200755A1 (en) 2020-06-25
US9921223B2 (en) 2018-03-20
EP3076949B1 (en) 2019-09-04
US20170059572A1 (en) 2017-03-02
AU2019201290A1 (en) 2019-03-14
CA2936100A1 (en) 2015-06-11
LT3076949T (lt) 2019-12-10
JP7138372B2 (ja) 2022-09-16
HUE046489T2 (hu) 2020-03-30
JP2019198327A (ja) 2019-11-21
JP2021177760A (ja) 2021-11-18
DK3076949T3 (da) 2019-11-25
AU2014360344B2 (en) 2018-11-29
AU2014360344A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
JP7138372B2 (ja) 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
EP3833760B1 (en) Microrna-based therapy targeted against lcp-1 positive cancers
CN113694075A (zh) 用于医治疾病的外泌体的用途
CN104080461A (zh) 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
SG188666A1 (en) Methods and reagents for detection and treatment of esophageal metaplasia
AU2018386215B2 (en) Methods and compositions for treating cancer using exosomes-associated gene editing
US20210369858A1 (en) Use of exosomes for targeted delivery of therapeutic agents
JP7602246B2 (ja) エキソソームを用いる腫瘍抑制因子の治療的調整法
CA3095136A1 (en) Use of exosomes for targeted delivery of therapeutic agents
WO2019191429A2 (en) Identification of epigenetic alterations in dna isolated from exosomes
US20220163532A1 (en) Nuclear-derived exosomes and methods of use thereof
HK1227707A1 (en) Method for isolating cancer cell-derived exoxomes
HK1227707B (en) Method for isolating cancer cell-derived exoxomes
Liang et al. Circ847 upregulation via CAFs suppresses salivary adenoid cystic carcinoma progression through VIM-EMT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190710

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20191023